Anthrax is an acute infectious disease caused by the spore-forming bacterium Bacillus anthracis. Anthrax most commonly occurs in wild and domestic lower vertebrates (cattle, sheep, goats, camels, antelopes, and other herbivores), but it can also occur in humans when they are exposed to infected animals or tissue from infected animals.
Anthrax is most common in agricultural regions where it occurs in animals. These include South and Central America, Southern and Eastern Europe, Asia, Africa, the Caribbean, and the Middle East. When anthrax affects humans, it is usually due to an occupational exposure to infected animals or their products. Workers who are exposed to dead animals and animal products from other countries where anthrax is more common may become infected with B. anthracis (industrial anthrax). Anthrax outbreaks occur in the United States on an annual basis in livestock and wild game animals such as deer.
Anthrax infection can occur in three forms: cutaneous (skin), inhalation, and gastrointestinal. B. anthracis spores can live in the soil for many years, and humans can become infected with anthrax by handling products from infected animals or by inhaling anthrax spores from contaminated animal products. Anthrax can also be spread by eating undercooked meat from infected animals. It is rare to find infected animals in the United States.
Researchers at Oregon State University have found a way to use magnetic "nanobeads" to help detect chemical and biological agents, with possible applications in everything from bioterrorism to medical diagnostics, environmental monitoring or even water and food safety.
PolyMedix, Inc., a biotechnology company focused on developing new therapeutic drugs to treat patients with acute infectious diseases and cardiovascular disorders, announced today that several of its defensin-mimetic antibiotic compounds have shown antimicrobial efficacy in an animal model against the bacteria that causes anthrax.
Aradigm Corporation today announced financial results for the fourth quarter and full year ended December 31, 2010.
Aradigm Corporation announced the last patient was enrolled in a Phase 2b study designed to evaluate the Company's inhaled liposomal ciprofloxacin (CFI, ARD-3100) in patients with non-cystic fibrosis bronchiectasis (BE), a severe progressive respiratory disease for which there is currently no approved treatment in the U.S.
Cangene Corporation today reports financial results for the quarter ended January 31, 2011, which have been prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB").
Response Biomedical Corporation reported that it recorded total revenues of $7,610,827 compared to $9,946,269 in 2009 and reduced operating expenses by 13% to $9,216,257 in 2010 from $10,602,954 in 2009.
Illicit drug users are at increased risk of being exposed to microbial pathogens and are more susceptible to serious infections say physicians writing in the Journal of Medical Microbiology.
Researchers at the Institute for Genome Sciences at the University of Maryland School of Medicine and collaborators at the FBI, the U.S. Army Medical Research Institute of Infectious Diseases and Northern Arizona University have published the first scientific paper based on their investigation into the anthrax attacks of 2001.
In 2001, a mystery perpetrator mailed a series of anthrax-laced letters to several locations, killing five people. In 2008, shortly after emerging as the prime suspect in an exhaustive investigation by the FBI, an Army microbiologist, Bruce Ivins, PhD, committed suicide. This morning, a National Academy of Sciences committee, charged in September 2008 with reviewing the scientific approaches used by the FBI in that investigation, released its report.
The Trust for America's Health (TFAH) applauds the President's budget for an overall increase in disease prevention funding, reflecting the new funds provided by the Prevention Fund from the Affordable Care Act (ACA), but expresses extreme concerns over the cuts to funding for core programs at the U.S. Centers for Disease Control and Prevention (CDC) and for emergency preparedness.
Today, at the American Society for Microbiology Conference on Biodefense and Emerging Diseases, scientists from Abbott Molecular presented data showing the unique power of the company's Ibis technology to identify and further characterize unknown disease-causing pathogens to help aid in the bioforensic analysis of pandemic outbreaks.
Soligenix, Inc., a late-stage biopharmaceutical company, today announced that it has entered into a definitive license agreement with the University of Colorado (CU) for novel technology for use in the development of subunit vaccines with long-term stability, including stability at elevated temperatures.
Soligenix, Inc., a late-stage biopharmaceutical company, announced today that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation to RiVax™ for the prevention of ricin intoxication. RiVax™ is a proprietary vaccine that contains a recombinant subunit of the A chain of ricin toxin which induces ricin neutralizing antibodies in humans and animals.
Few strands of bacteria have achieved such a central place in public consciousness as Bacillus anthracis, the bacteria which causes Anthrax. While today it is a feared weapon of bioterrorism Bacillus anthracis has played a significant historical role, especially through the research of the celebrated 19th century scientists Robert Koch and Louis Pasteur, in shaping our understanding of infectious diseases and immunology
At issue are charges to public hospitals and clinics that treat a large number of poor patients and a Vermont law that restricts prescription drug data.
Impax Laboratories, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted final approval of the Company's Abbreviated New Drug Application for the generic version of Doryx® (doxycyline hyclate delayed-release) 75 and 100mg tablets. The Company is preparing for product launch through Global Pharmaceuticals, Impax's generic division.
Emergent BioSolutions today announced the initiation of a Phase I clinical trial for NuThraxTM, also known as AV7909, with the dosing of the first subject.
Response Biomedical Corporation today announced that the United States Patent and Trademark Office issued an official Notice of Allowance on one of the Company's patent applications regarding the RAMP® technology. The patent entitled "Comparative Multiple Analyte Immunoassay" is expected to issue in the first quarter of 2011.
Pulmatrix, a clinical stage biotechnology company discovering and developing a new class of therapies for the prevention, treatment and control of respiratory diseases, today announced that it has been awarded a grant for $5.7 million from the Defense Advanced Research Projects Agency (DARPA), a component of the Department of Defense (DOD), focused on identifying and advancing novel technologies to support defense of our nation's soldiers and civilian population.
Scientists at Seattle Biomedical Research Institute and Northwestern University Feinberg School of Medicine have reached a major milestone in the effort to wipe out some of the most lethal diseases on the planet.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.